An interventional study of myota's prebiotic fibre blend in Metabolic Syndrome, Anxiety and Mood, sponsored by Myota GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-23.
Sponsored by Myota GmbH · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Metabolic Syndrome with a site in United Kingdom — 9 open to participants now, 10 under way, none of them phase 3. Metabolic Syndrome · United Kingdom.
Among the 55 studies in Metabolic Syndrome with a site in United Kingdom, this one is the 19th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2023, is one of 40 with no phase, and was the 45th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →9 of the 55 studies in Metabolic Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Liverpool · Sites in United Kingdom
Ages 40+ · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 50–65 · Healthy volunteers
University of Central Lancashire · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Eclat Srl. · Sites in United Kingdom
Ages 23+
Salah Snouda · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 45 across the 48 interventional studies, 100 across the 7 observational. Of the 40 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 55 have an industry lead sponsor. The 10 most frequent:
Myota GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Myota GmbH has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07606872Salah SnoudaValidation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes | 2026-12 |
| NCT06795438University of Central LancashireEffects of Green Tea on Cardiometabolic Outcomes | 2027-02-01 |
| NCT07474233Liverpool John Moores UniversityAssociations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health | 2027-05 |
| NCT07462871Liverpool John Moores UniversityComparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health | 2027-06 |
| NCT06784154University of LiverpoolThe Role of Ectopic Fat and Heart Attack Risk in HIV | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Metabolic Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome. This study will help shape a larger randomised controlled study (RCT) powered to assess efficacy in a bigger cohort of patients.
Primary outcome measures will explore the efficacy of a prebiotic fibre blend on systemic inflammation. Secondary and exploratory outcomes measures will explore the efficacy of the prebiotic blend on clinical biomarkers associated with cardiometabolic risk factors, microbiota features, and mental health. Using these data, we will also estimate in-year savings for the NHS in the metabolic syndrome population on a per participant basis.
Metabolic syndrome is not a chronic disease, but a cluster of metabolic abnormalities including central obesity, insulin resistance, hyperglycemia, hypertension, and dyslipidemia. In the UK, it's estimated that 1 in 3 adults aged 50 years or over meets the criteria of metabolic syndrome. Emerging evidence suggests that metabolic syndrome is associated with low-grade systemic inflammation, which is thought to play a critical role in the subsequent pathogenesis of various metabolic and cardiovascular diseases. In fact, the inflammatory biomarker, high-sensitivity (hs)-CRP, has been shown to be predictive of whether metabolic syndrome progresses to a chronic disease, including cardiovascular disease (CVD), type 2 diabetes (T2D), and cancer mortality. Alongside metabolic disturbances, recent studies have shown that repeated (or long-term) exposure to systemic inflammation is also associated with an increased risk of future depressive and anxiety symptoms, potentially acting via the blood-brain barrier (BBB) interface.
From both a physical and mental health standpoint, it's clear that novel interventions, beyond pharmacotherapy, are needed to reverse the progression of metabolic syndrome, and reduce the risk of developing a long-term chronic disease, and poor mental health.
It is well established that dietary fibre plays a critical role in reducing symptoms of metabolic syndrome, including improvements in insulin sensitivity, glucose metabolism, lipid profile, and blood pressure. Specifically, dietary fibre has been shown to reduce cholesterol levels by binding to bile acids and promoting their excretion, as well as by decreasing the absorption of dietary cholesterol. Additionally, dietary fibre can slow the absorption of carbohydrates and reduce post-prandial glucose spikes, which may contribute to improvements in insulin sensitivity and metabolic health.
Growing evidence also suggests that the mechanisms underlying the benefits of fibre are thought to be mediated, at least in part, by the gut microbiota and their metabolites, such as short-chain fatty acids (SCFAs). A recent systematic review and meta-analysis of 10 randomised controlled trials found that increased intake of dietary fibre was associated with significant improvements in fasting glucose, insulin resistance, total cholesterol, and low-density lipoprotein (LDL) cholesterol levels in individuals with type 2 diabetes. Furthermore, a randomised controlled trial in individuals with metabolic syndrome found that supplementation with a prebiotic fibre blend led to significant reductions in fasting glucose, insulin resistance, and inflammatory markers. Therefore, increasing prebiotic fibre intake may represent a promising strategy for the prevention and management of metabolic symptoms, but remains poorly understood.
Prebiotics are specific types of fibres found in foods like onion, garlic, artichokes, asparagus, leeks, and chicory root. However, to reap the benefits of prebiotics for given health indications, this requires someone to consume roughly 5-10 onions a day. Prebiotic fibre blends (in powder form) are derived from a diversity of plant-based sources, and allows for the study of prebiotic-based benefits in a feasible, easy, measurable, and controlled way.
In this current study, we aim to assess the effects of a daily prebiotic fibre blend on systemic inflammation, the gut microbiome, lipid profiles, and self-report measures of mental health in individuals with metabolic syndrome. The study will be conducted over 12 weeks, and the findings may provide new insights into the potential role of prebiotics in the prevention and management of physical and mental health risk factors associated with chronic disease.
The study population will include adults aged 18-75 years who meet the criteria for metabolic syndrome. To promote the inclusion and diversity of participants across England, this study will be conducted remotely, by posting participants the at-home collection kits (stool and finger prick tests) and online surveys. This gives access to participants who would otherwise not be able to take part in research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The treatment group will consume 10g per day of a diverse prebiotic fibre supplement. Supplements are powdered and unflavoured, and given to the participants in 300g packets lasting for 30 days. A 10g scoop is included in each packet and participants are advised to consume one level scoop at any time of the day. Participants are provided with examples on how to consume the supplement (e.g., breakfast cereal, coffee, tea, water).
Dietary Supplement: myota's prebiotic fibre blend
Participants are provided with standard of care (dietary advice). Recommendations for diet and lifestyle advice are provided by a UK-registered GP, and follow the Heart UK's Healthy Eating Guidelines. These recommendations emphasise a Mediterranean diet, rich in fruit, vegetables, and healthy fats (omega-3 fatty acids), while reducing refined sugar, salt, processed foods, and alcohol intake. The Mediterranean diet is considered a gold-standard for participants with MetS and poor mental health.
Dietary Supplement: myota's prebiotic fibre blend
Each 10g daily serve of supplement contains the following fibres: * Fructooligosaccharides * Inulin * Resistant dextrin * Resistant maltodextrin * Partially hydrolysed guar gum * Guar gum
C-Reactive Protein
To compare the effect of Myota's prebiotic fibre blend versus standard of care on C-Reactive Protein levels
Time frame: Baseline and Week 12
Depression, Anxiety and Stress Scale (42-item)
To compare the effect of Myota's prebiotic fibre blend versus standard of care on Depression, Anxiety and Stress Scale (42-item) scores. Minimum score = 0, maximum score = 126, where higher scores indicate worse outcomes.
Time frame: Baseline and Week 12
Patient Health Questionnaire (PHQ)
To compare the effect of Myota's prebiotic fibre blend versus standard of care on Patient Health Questionnaire scores. Minimum score = 1, maximum score = 27, where higher scores indicate worse outcomes.
Time frame: Baseline and Week 12
Perceived Stress Scale (PSS)
To compare the effect of Myota's prebiotic fibre blend versus standard of care on Perceived Stress Scale scores. Minimum score = 0, maximum score = 40, where higher scores indicate worse outcomes.
Time frame: Baseline and Week 12
Generalised Anxiety Disorder (GAD) Scale
To compare the effect of Myota's prebiotic fibre blend versus standard of care on Generalised Anxiety Disorder Scale scores. Minimum score = 0, maximum score = 21, where higher scores indicate worse outcomes.
Time frame: Baseline and Week 12
Gastrointestinal Symptom Rating Scale (GSRS)
To compare the effect of Myota's prebiotic fibre blend versus standard of care on Gastrointestinal Symptom Rating Scale scores. Scores are calculated for 5 sub-categories: reflux, pain, constipation, diarrhoea, indigestion, where the minimum score is 1 and maximum score is 21, where higher scores indicate worse outcomes.
Time frame: Baseline and Week 12
Gut Microbiome Profiles
To compare the effect of Myota's prebiotic fibre blend versus standard of care on gut microbiome profiles
Time frame: Baseline and Week 12
Lipid Profiles
To compare the effect of Myota's prebiotic fibre blend versus standard of care on lipid profiles
Time frame: Baseline and Week 12
Diastolic blood pressure
To compare the effect of Myota's prebiotic fibre blend versus standard of care on diastolic blood pressure.
Time frame: Baseline and Week 12
Systolic Blood pressure
To compare the effect of Myota's prebiotic fibre blend versus standard of care on systolic blood pressure.
Time frame: Baseline and Week 12
Dietary fibre intake
Assess the difference in dietary fibre intake as a confounding variable.
Time frame: Baseline and Week 12
Plan to share: No — De-identified participants data may be available to other researchers upon reasonable request.
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Dec 2023, 6 months.
Of 50 industry-sponsored interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 6 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myota GmbH